Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

24.01.2023 | short review

Update on systemic therapy for clear cell renal cell carcinoma

verfasst von: Dr. Josef Mühlmann

Erschienen in: memo - Magazine of European Medical Oncology

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

The treatment landscape of advanced and metastatic renal cell carcinoma (RCC) has changed fundamentally over the last two decades with the introduction of tyrosine kinase inhibitors (TKIs) in 2005 and immune checkpoint inhibitors (ICIs) about 10 years later, both demonstrating significantly improved overall survival (OS) rates across all RCC risk categories. Currently, combination therapies represent the standard-of-care in the first-line setting of clear cell RCC in almost all cases. In this short review article, the most recent therapeutic advances in early and advanced stage of clear cell RCC are summarized.
Literatur
1.
Zurück zum Zitat Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683–94. CrossRef Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683–94. CrossRef
2.
Zurück zum Zitat Choueiri TK, Tomczak P, Park SH, et al. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. J Clin Oncol. 2022;40(6_suppl):290. CrossRef Choueiri TK, Tomczak P, Park SH, et al. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. J Clin Oncol. 2022;40(6_suppl):290. CrossRef
3.
Zurück zum Zitat Motzer RJ, Russo P, Guenwald V, et al. Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial. Ann Oncol. 2022;33(7_suppl):S808–S69. Motzer RJ, Russo P, Guenwald V, et al. Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial. Ann Oncol. 2022;33(7_suppl):S808–S69.
4.
Zurück zum Zitat Bex A, Uzzo R, Karam JA, Master VA, et al. IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection. Ann Oncol. 2022;33(7_suppl):S808–S69. Bex A, Uzzo R, Karam JA, Master VA, et al. IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection. Ann Oncol. 2022;33(7_suppl):S808–S69.
5.
Zurück zum Zitat Allaf M, Kim SE, Harshman LC, McDermott DF, et al. Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. Ann Oncol. 2022;33(7_suppl):S808–S69. Allaf M, Kim SE, Harshman LC, McDermott DF, et al. Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. Ann Oncol. 2022;33(7_suppl):S808–S69.
6.
Zurück zum Zitat Powels T, Albiges L, Bex A, et al. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32(12):1511–9. CrossRef Powels T, Albiges L, Bex A, et al. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32(12):1511–9. CrossRef
7.
Zurück zum Zitat Motzer RJ, Tannir NM, McDermott DF, et al. Conditional survival and 5‑year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). Ann Oncol. 2021;32(suppl_5):S678. Motzer RJ, Tannir NM, McDermott DF, et al. Conditional survival and 5‑year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). Ann Oncol. 2021;32(suppl_5):S678.
8.
Zurück zum Zitat Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5‑year minimum follow-up. J Clin Oncol. 2022;40(6_suppl):352. CrossRef Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5‑year minimum follow-up. J Clin Oncol. 2022;40(6_suppl):352. CrossRef
9.
Zurück zum Zitat Rini BL, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. J Clin Oncol. 2021;39(15_suppl):4500. CrossRef Rini BL, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. J Clin Oncol. 2021;39(15_suppl):4500. CrossRef
10.
Zurück zum Zitat Powels T, Choueiri TK, Burotto M, Escudier B, et al. Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma. J Clin Oncol. 2022;40(6_suppl):350. CrossRef Powels T, Choueiri TK, Burotto M, Escudier B, et al. Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma. J Clin Oncol. 2022;40(6_suppl):350. CrossRef
11.
Zurück zum Zitat Motzer R, Alekseev B, Rha SY, Porta C, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–300. CrossRef Motzer R, Alekseev B, Rha SY, Porta C, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–300. CrossRef
12.
Zurück zum Zitat Choueiri TK, Powels TB, Albiges L, Burotto M, et al. Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). Ann Oncol. 2022;33(7_suppl):S808–S69. Choueiri TK, Powels TB, Albiges L, Burotto M, et al. Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). Ann Oncol. 2022;33(7_suppl):S808–S69.
13.
Zurück zum Zitat Recio-Boiles A, et al. Network meta-analysis (NMA) of second-line (2L) treatment options in metastatic renal cell carcinoma. J Clin Oncol. 2022;40(6_suppl):337. CrossRef Recio-Boiles A, et al. Network meta-analysis (NMA) of second-line (2L) treatment options in metastatic renal cell carcinoma. J Clin Oncol. 2022;40(6_suppl):337. CrossRef
14.
Zurück zum Zitat Motzer RJ, Hutson TE, Glen H, Michaelson MD, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82. CrossRef Motzer RJ, Hutson TE, Glen H, Michaelson MD, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82. CrossRef
15.
Zurück zum Zitat Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477–90. CrossRef Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477–90. CrossRef
16.
Zurück zum Zitat Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385(22):2036–46. CrossRef Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385(22):2036–46. CrossRef
17.
Zurück zum Zitat Bauer TM, Chouieri TK, Papadopoulos KP, et al. The oral HIF‑2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma: updated follow-up of a phase I/II study. J Clin Oncol. 2021;39(6_suppl):273. CrossRef Bauer TM, Chouieri TK, Papadopoulos KP, et al. The oral HIF‑2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma: updated follow-up of a phase I/II study. J Clin Oncol. 2021;39(6_suppl):273. CrossRef
18.
Zurück zum Zitat Choueiri TK, Albiges L, Fan L, Perini RF, et al. Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2020;38(15_suppl):TPS5094. CrossRef Choueiri TK, Albiges L, Fan L, Perini RF, et al. Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2020;38(15_suppl):TPS5094. CrossRef
19.
Zurück zum Zitat Calvo E, Boni V, Chaudhry A, Debruyne PR, et al. Nemvaleukin alfa in patients with advanced renal cell carcinoma: ARTISTRY‑1. J Clin Oncol. 2022;40(6_suppl):330. CrossRef Calvo E, Boni V, Chaudhry A, Debruyne PR, et al. Nemvaleukin alfa in patients with advanced renal cell carcinoma: ARTISTRY‑1. J Clin Oncol. 2022;40(6_suppl):330. CrossRef
Metadaten
Titel
Update on systemic therapy for clear cell renal cell carcinoma
verfasst von
Dr. Josef Mühlmann
Publikationsdatum
24.01.2023
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00867-w